The future of rheumatic fever

  • Angelo Taranta
  • Milton Markowitz


Futurology is a dangerous vocation; dangerous, that is, to the reputation of futurologists. Nevertheless, the temptation is irresistible to look, however briefly, into the crystal ball.


Rheumatic Fever Rheumatic Heart Disease Streptococcal Infection Acute Rheumatic Fever Cyanogen Bromide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stollerman, G. H. (1978). Streptococcal immunology: Protection vs. injury. Ann. Intern. Med., 80, 422Google Scholar
  2. 2.
    Phillips, G. N. Jr et al. (1981). Streptococcal M protein: alpha-helical coiled-coil structure and arrangement on the cell surface. Proc. Natl. Acad. Sci., U.S.A., 78, 4689PubMedCrossRefGoogle Scholar
  3. 3.
    Beachey, E. H. and Stollerman, G. H. (1972). The common antigen(s) of streptococcal M protein vaccines causing hyperimmune reactions in man. Trans. Assoc. Am. Phys., 85, 212PubMedGoogle Scholar
  4. 4.
    Cunningham, M. and Beachey, E. H. (1975). Immunochemical properties of streptococcal M protein purified by isoelectric focusing. J. Immunol., 115, 1002PubMedGoogle Scholar
  5. 5.
    Beachey, E. H. et al. (1984). Epitope specific protective immunogenicity of chemically synthesized 12, 18 and 23 residue peptide fragments of streptococcal M protein. Proc. Natl. Acad. Sci., U.S.A., 81, 2203PubMedCrossRefGoogle Scholar
  6. 6.
    Beachey, E. H. and Seyer, J. M. (1986). Protective and non-protective epitopes of chemically synthesized peptides of the NH2-terminal region of type 6 streptococcal M protein. J. Immunol., 136, 2287PubMedGoogle Scholar
  7. 7.
    Beachey, E. H. et al. (1977). Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the aminoterminal region of type 24 M antigen. J. Exp. Med., 145, 1469PubMedCrossRefGoogle Scholar
  8. 8.
    Beachey, E. H. et al. (1977). Separation of the type specific M protein from toxic cross reactive antigens of group A streptococci. Trans. Assoc. Am. Phys., 90, 390PubMedGoogle Scholar
  9. 9.
    Beachey, E. H. et al. (1978). Repeating covalent structure of streptococcal M protein. Proc. Natl. Acad. Sci., U.S.A., 75, 3163PubMedCrossRefGoogle Scholar
  10. 10.
    Fischetti, V. A. et al. (1976). Streptococcal M protein extracted by nonionic detergent. I. Properties of the antiphagocytic and type-specific molecules. J. Exp. Med., 144, 32PubMedCrossRefGoogle Scholar
  11. 11.
    Zabriskie, J. B. et al. (1985). Rheumatic fever-associated B cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum., 28, 1047PubMedCrossRefGoogle Scholar
  12. 12.
    Wood, H. F. et al. (1964). Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. III. Comparative effectiveness of three prophylaxis regimens in preventing streptococcal infections and rheumatic recurrences. Ann. Intern. Med., 60 (Feb. Suppl.), 31Google Scholar
  13. 13.
    Wannamaker, L. W. et al. (1951). Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am. J. Med., 10, 673PubMedCrossRefGoogle Scholar
  14. 14.
    Rheumatic Fever and Rheumatic Heart Disease Study Group, Inter-Society Commission for Heart Disease Resources (1970). Prevention of rheumatic fever and rheumatic heart disease. Circulation, 41, A1–A15Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Angelo Taranta
    • 1
    • 2
  • Milton Markowitz
    • 3
  1. 1.New York Medical CollegeNew York CityUSA
  2. 2.Cabrini Medical CenterNew York CityUSA
  3. 3.University of Connecticut School of MedicineFarmingtonUSA

Personalised recommendations